Literature DB >> 20056650

Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens.

Jessica M Faupel-Badger1, Barbara J Fuhrman, Xia Xu, Roni T Falk, Larry K Keefer, Timothy D Veenstra, Robert N Hoover, Regina G Ziegler.   

Abstract

Absolute and relative concentrations of estrogens and estrogen metabolites are important for clinical decisions as well as for epidemiologic, experimental, and clinical research on hormonal carcinogenesis. RIA and ELISA are routinely used for measuring estrogen metabolites in blood and urine due to efficiency and low cost. Here, we compare absolute and ranked concentrations of estrone, estradiol, and estriol measured by indirect RIA and of 2-hydroxyestrone and 16alpha-hydroxyestrone measured by ELISA to the concentrations obtained using a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which measures 15 estrogen metabolites concurrently. We used overnight urine samples collected from control women (362 premenopausal and 168 postmenopausal) participating in a population-based case-control study of breast cancer among Asian American women ages 20 to 55 years. When comparing RIA or ELISA levels to LC-MS/MS, absolute concentrations for the five estrogen metabolites ranged from 1.6 to 2.9 and 1.4 to 11.8 times higher in premenopausal and postmenopausal women, respectively (all P < 0.0001). However, LC-MS/MS measurements were highly correlated [Spearman r (r(s)) = 0.8-0.9] with RIA and ELISA measurements in premenopausal women and moderately correlated (r(s) = 0.4-0.8) in postmenopausal women. Measurements of the 2-hydroxyestrone:16alpha-hydroxyestrone ratio, a putative biomarker of breast cancer risk, were moderately correlated in premenopausal women (r(s) = 0.6-0.7) but only weakly correlated in postmenopausal women (r(s) = 0.2). LC-MS/MS had higher intraclass correlation coefficients (> or =99.6%) and lower coefficients of variation (< or =9.4%) than ELISA (> or =97.2% and < or =14.2%) and RIA (> or =95.2% and < or =17.8%). Comparison with the LC-MS/MS method suggests that the widely used RIA and ELISA estrogen metabolite measures may be problematic, especially at low estrogen metabolite levels characteristic of postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056650      PMCID: PMC2836837          DOI: 10.1158/1055-9965.EPI-09-0643

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  Comparison of methods to measure low serum estradiol levels in postmenopausal women.

Authors:  Jennifer S Lee; Bruce Ettinger; Frank Z Stanczyk; Eric Vittinghoff; Vladimir Hanes; Jane A Cauley; Walt Chandler; Jim Settlage; Mary S Beattie; Elizabeth Folkerd; Mitch Dowsett; Deborah Grady; Steven R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2006-08-01       Impact factor: 5.958

Review 2.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

3.  A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid.

Authors:  R T Falk; S C Rossi; T R Fears; D W Sepkovic; A Migella; H Adlercreutz; J Donaldson; H L Bradlow; R G Ziegler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

4.  Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.

Authors:  A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

5.  Standardization of steroid hormone assays: why, how, and when?

Authors:  Frank Z Stanczyk; Jennifer S Lee; Richard J Santen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-09       Impact factor: 4.254

6.  Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.

Authors:  Richard J Santen; Lawrence Demers; Susan Ohorodnik; J Settlage; Peter Langecker; D Blanchett; Paul E Goss; Shuping Wang
Journal:  Steroids       Date:  2007-05-21       Impact factor: 2.668

7.  Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women.

Authors:  A Zeleniuch-Jacquotte; P Toniolo; M Levitz; R E Shore; K L Koenig; S Banerjee; P Strax; B S Pasternack
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-12       Impact factor: 4.254

Review 8.  Estrogen hydroxylation--the good and the bad.

Authors:  Daniel W Sepkovic; H Leon Bradlow
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

9.  A liquid chromatography-mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites.

Authors:  Xia Xu; Larry K Keefer; Regina G Ziegler; Timothy D Veenstra
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

10.  Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry.

Authors:  Xia Xu; John M Roman; Haleem J Issaq; Larry K Keefer; Timothy D Veenstra; Regina G Ziegler
Journal:  Anal Chem       Date:  2007-09-12       Impact factor: 6.986

View more
  33 in total

Review 1.  A review of cancer in U.S. Hispanic populations.

Authors:  Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

Review 2.  Epidemiologic studies of estrogen metabolism and breast cancer.

Authors:  Regina G Ziegler; Barbara J Fuhrman; Steven C Moore; Charles E Matthews
Journal:  Steroids       Date:  2015-02-26       Impact factor: 2.668

3.  Circulating estrogen metabolites and risk of breast cancer in postmenopausal women.

Authors:  Alan A Arslan; Karen L Koenig; Per Lenner; Yelena Afanasyeva; Roy E Shore; Yu Chen; Eva Lundin; Paolo Toniolo; Göran Hallmans; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

4.  Estrogen metabolism and mammographic density in postmenopausal women: a cross-sectional study.

Authors:  Barbara J Fuhrman; Louise A Brinton; Ruth M Pfeiffer; Xia Xu; Timothy D Veenstra; Barbara E Teter; Celia Byrne; Cher M Dallal; Maddalena Barba; Paola C Muti; Gretchen L Gierach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 5.  A new approach to measuring estrogen exposure and metabolism in epidemiologic studies.

Authors:  R G Ziegler; J M Faupel-Badger; L Y Sue; B J Fuhrman; R T Falk; J Boyd-Morin; M K Henderson; R N Hoover; T D Veenstra; L K Keefer; X Xu
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-09       Impact factor: 4.292

6.  Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

Authors:  Jennifer T Loud; Gretchen L Gierach; Timothy D Veenstra; Roni T Falk; Kathryn Nichols; Allison Guttmann; Xia Xu; Mark H Greene; Mitchell H Gail
Journal:  Breast Cancer Res Treat       Date:  2014-01-18       Impact factor: 4.872

7.  Accurate determination of tissue steroid hormones, precursors and conjugates in adult male rat.

Authors:  Naoyuki Maeda; Emi Tanaka; Tomokazu Suzuki; Kanako Okumura; Sachiko Nomura; Taku Miyasho; Satoko Haeno; Hiroshi Yokota
Journal:  J Biochem       Date:  2012-10-10       Impact factor: 3.387

Review 8.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

9.  A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis.

Authors:  Ju-Yeon Moon; Kwang Joon Kim; Myeong Hee Moon; Bong Chul Chung; Man Ho Choi
Journal:  J Lipid Res       Date:  2011-05-21       Impact factor: 5.922

10.  Urinary estrogen metabolites during a randomized soy trial.

Authors:  Yukiko Morimoto; Shannon M Conroy; Ian S Pagano; Marissa Isaki; Adrian A Franke; Frank J Nordt; Gertraud Maskarinec
Journal:  Nutr Cancer       Date:  2012-01-31       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.